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MetalloproteinaseMMP-11 (stromelysin-3) is a matrix metalloproteinase associated with tumor progression and poor progno-
sis. Its expression was initially described exclusively in stromal cells surrounding tumors, but more recently it
has also been detected in macrophages and hepatocarcinoma cells. Here we show MMP-11 expression in
human epithelial colon adenocarcinoma cell lines (Caco-2, HT-29 and BCS-TC2). Treatment of BCS-TC2
cells with butyrate and trichostatin A (TSA) (histone deacetylase inhibitors) increases MMP11 promoter ac-
tivity and protein expression. Using electrophoretic mobility shift assay (EMSA) and supershift assays, we
demonstrate for the ﬁrst time that Sp1 is able to bind to the GC-boxes within theMMP11 proximal promoter
region; this binding has been conﬁrmed by chromatin immunoprecipitation. Sp1 is involved inMMP11 basal
expression and it is essential for the upregulation of transcription by histone deacetylase inhibitors as de-
duced from mutant constructs lacking the Sp1 sites and by inhibition of its binding to the promoter with
mithramycin. This regulation requires the formation of Sp1/Smad2 heterocomplexes, which is stimulated
by an increase in the acetylation status of Smad after butyrate or TSA treatments. We have also found that
ERK1/2-mitogen-activated protein kinase (MAPK), but not p38-MAPK or JNK, is involved in the upregulation
of MMP11 by HDAC inhibitors.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Matrix metalloproteinases (MMPs) are a well conserved family of
zinc-dependent endopeptidases involved in the degradation of the
extracellular matrix during remodeling processes of both normal
and pathological tissues, such as embryogenic development, wound
healing, inﬂammation, angiogenesis or tumor progression [1]. The
members of this family have a conserved catalytic domain, a signal
peptide which directs the secretion process and a propeptide region
to maintain enzyme latency. The majority of MMPs have a
hemopexin-like domain that is responsible for the substrate speciﬁc-
ity and for the interaction with endogenous inhibitors (TIMPs, tissue
inhibitor of metalloproteinases) [1,2]. MMPs are either secreted or
anchored to the cell membrane, where they exert their catalytic activ-
ity over substrates within the pericellular space.
The expression and activation of MMPs are tightly regulated. The
activity of MMPs is controlled at several levels to ensure that their
degradative functions are conﬁned to those places or situationsmitogen-activated protein ki-
hibitor of metalloproteinases;
+34 91 394 4159.
.
l rights reserved.where it is necessary. The MMPs are expressed as inactive proen-
zymes that require the removal of the propeptide region to switch
on their protease activity. Alternatively, MMP-11, MMP-23, MMP-28
and membrane-type MMPs can be activated intracellularly by furin-
like serine proteases and then either secreted or bound to the cell sur-
face [3]. MMPs are strongly regulated by tissue speciﬁc location or by
inactivation by TIMPs [2].
Human MMP-11, also known as stromelysin-3, differs drastically
from other MMPs in its catalytic targets: β-casein, insulin-like growth
factor-binding protein-1 (IG-FBP-1), α2-macroglobulin, serine pro-
teinase inhibitors (such as α1-proteinase inhibitor, α1PI, and α2-
antiplasmin), the laminin receptor and type VI collagen [4]. In
addition to substrate speciﬁcity and proteolytic activation, MMP-11
differs from other MMPs in its transcriptional regulation [5,6]. Its ex-
pression is stimulated by retinoic acid through a retinoic acid-
response element (RARE) located in its proximal promoter in which
there is no AP-1 site [7].
MMP-11 was ﬁrst described in stromal cells surrounding breast
neoplastic cells [8] and was later detected in the stroma of other tu-
mors, such as non-small cell lung cancer [9,10] or colorectal carcino-
mas [11], as well as in macrophages [12], and in Hca-F mouse
hepatocarcinoma cells [13]. High levels of MMP-11 protein and
mRNA have been correlated with a poor prognosis in carcinomas; in
addition, it has been described as a predictive tumor biomarker in
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due to its proteolytic activity, as suggested by the results obtained
in vivo using MMP-11 catalytic inactive mutants [16], although the
molecular mechanisms involved are yet unknown. One hypothesis
is that the degradation of protease inhibitors, as α1PI (elastase inhib-
itor) or α2-antiplasmin, by MMP-11 may increase tissue damage by
activation of pro-MMPs including pro-MMP-11 [17]. Moreover, it
has been suggested that MMP-11 improves cancer cell survival and
could inhibit apoptosis [18,19]. Regarding the physiological role of
MMP-11 little is known although several authors have suggested its
involvement in development and organ remodeling being these pro-
cesses correlated with apoptosis induction (for review see [20]).
Butyrate is a natural histone deacetylase (HDAC) inhibitor pro-
duced in the colon by fermentation of diet-ﬁber, where it represents
the main energy source for colonocytes in vivo. It is essential for the
maintenance of the colonic epithelium homeostasis and is able to in-
duce cell cycle arrest, differentiation and apoptosis in several normal
and transformed cell lines [21,22]. These effects are believed to result
from changes in the gene expression proﬁle promoted by the HDAC
inhibition [22,23]. There are mainly two types of genes whose expres-
sion is regulated by butyrate: ﬁrst, genes characterized by the pres-
ence of CCAAT boxes on their promoters that are regulated by NF-Y
(Nuclear transcription Factor Y) and C/EBP (CCAAT/Enhancer-Binding
Protein) in response to butyrate and other HDAC inhibitors [24]; sec-
ond, genes with GC-boxes on their promoters that are mainly regulat-
ed by Sp1/Sp3 (i.e. p21) [25]. In addition, trichostatin A (TSA) is an
antifungal antibiotic derived from Streptomyces and a potent revers-
ible HDAC inhibitor that also modiﬁes gene expression proﬁles.
In this work we present evidence that MMP-11 is expressed not
only in stromal cells but also in human colon adenocarcinoma cells
(HT-29, Caco-2 and BCS-TC2), and we have further studied the ex-
pression of MMP11 in the BCS-TC2 cell line. These epithelial-like
cells are non-tumorigenic and poorly differentiated, and butyrate
treatment induces growth arrest, differentiation and apoptosis [21].
Here we propose Sp1 as an important transcription factor regulating
the basal expression of the MMP11 gene in cooperation with Smad2.
Taking into account that the acetylation status of histones and tran-
scription factors is probably involved in the transcriptional regulation
ofMMP genes [26], we have analyzed the effect of HDAC inhibitors in
the expression of this MMP. We provide evidence that MMP11 pro-
moter is activated after treatment with butyrate or TSA through two
different mechanisms: i) the increased acetylation of Smad2, which
promotes the formation of a Sp1/Smad2 complex bound to the
MMP11 proximal promoter region and, ii) the activation of ERK1/2-
mitogen-activated protein kinase (MAPK).
2. Materials and methods
2.1. Cell culture and treatments
The establishment and characterization of the human colon ade-
nocarcinoma BCS-TC2 cell line has been previously described [27].
BCS-TC2 epithelial cells were obtained in our laboratory from a poorly
differentiated human colon adenocarcinoma; they present a low dif-
ferentiation degree and null tumorigenicity in vivo. The human epi-
thelial colon adenocarcinoma cell lines HT-29 (ATCC: HTB38) and
Caco-2 (ATCC: HTB37), as well as the human rhabdomyosarcoma
cell line RD (ATCC: CCL-136) were also used. Routinely, cells were
cultured in Dulbecco's modiﬁed Eagle's medium containing 4.5 g/l
glucose, and supplemented with 5% heat-inactivated fetal calf serum
(10% for Caco-2 and RD cells), penicillin (50 IU/ml), streptomycin
(50 μg/ml) and glutamine (300 μg/ml). Cell harvesting was per-
formed by trypsinization.
Butyrate (Sigma, Alcobendas, Spain) was prepared in standard
culture medium and ﬁlter sterilized, and was used at 4 mM unless
otherwise stated. TSA (Sigma) was prepared in DMSO and added tothe cells at 0.5 μM. Mithramycin A (Sigma) was prepared in methanol
and added to the cells at 200 nM. Cultures containing the same
amount of DMSO or methanol were used as controls of TSA and
mithramycin A treatments, respectively. Incubation with the different
agents was performed on exponentially growing cells (2–3 days after
seeding) for 24 or 48 h.
Conditioned media were obtained after incubation of subconﬂu-
ent (~80% conﬂuence) human colon adenocarcinoma cells in serum-
free media for 48 h, and in the case of BCS-TC2 cells with the corre-
sponding treatments. Conditionedmedia from RD cells were collected
after 24 h incubation in the absence or presence of 10 ng/ml 4α-
phorbol 12-myristate 13-acetate, 1 μM all-trans or 9-cis retinoic acid
(PMA, t-RA or 9c-RA, respectively; all from Sigma). All media were
collected and concentrated 40-fold by centrifugation with Vivaspin
concentrators 10,000 MWCO (Vivascience, Sartorius, Madrid, Spain).
α2-Macroglobulin entrapment assay was performed as described
previously [17]. This protein tightly binds to and entraps the active
form of several MMPs. Brieﬂy, aliquots of MMP-11-containing condi-
tioned media were incubated with 10 μg of human α2-macroglobulin
(Sigma) for 12 h at 37 °C. Samples were then analyzed by Western
blot.
2.2. Antibodies
ForWestern blot, immunoprecipitation, and ChIP analyses, the fol-
lowing antibodies were used: mouse monoclonal antibodies anti-
humanMMP-11 (SL3-05), MMP-2 (42-5D11) (both from Calbiochem,
Madrid, Spain), acetyl-Lysine (4G12, Cell Signaling, Danvers, MA),
anti-human p53 (Ab-6 clone DO-1, ThermoScientiﬁc, Madrid,
Spain), and lamin B1 (MBL, Woburn, MA), and goat polyclonal anti-
bodies anti-human Sp1 (PEP2), Sp3 (D-20), MAZ (A-17), ZBP-89 (S-
15), Smad2/3 (E-20), phospho-Smad2/3 (Ser 423/425, sc-11769)
(all from Santa Cruz Biotechnology, Santa Cruz, CA), phospho-
Smad3, Ser423/425 (C25A9; Cell Signaling, Beverly, MA), and
phospho-Sp1 (phospho T453; Abcam, Cambridge, UK). Peroxidase-
conjugated rabbit anti-goat IgG was from Jackson Immunoresearch
Laboratories (West Grove, PA) and goat anti-mouse IgG was from
Thermo Scientiﬁc (Madrid, Spain). Peroxidase-conjugated mouse
TrueBlot ULTRA anti-mouse IgG and peroxidase-conjugated goat
TrueBlot anti-goat IgG were from eBiosciences (Hatﬁeld, UK). For
ﬂow cytometry, the primary goat polyclonal antibody anti-human
MMP-11 (C-20, Santa Cruz Biotechnology) and FITC-conjugated rab-
bit anti-goat IgG (Jackson Immunoresearch Laboratories) monoclonal
antibody were used.
2.3. Western blot analysis of nuclear extracts and conditioned media
Nuclear extracts were obtained as described [24]. Brieﬂy, har-
vested cells (20–30×106) were washed twice with ice-cold PBS,
resuspended in 180 μl of ice-cold hypotonic lysis buffer (10 mM
Hepes pH 7.9, 10 mM KCl, 0.1 mM EDTA) containing protease and
phosphatase inhibitors (PMSF, aprotinin, pepstatin A, leupeptin,
Na3VO4, NaF, β-glycerophosphate, dithiothreitol, all at 1 μM ﬁnal con-
centration), incubated on ice for 10 min followed by addition of 20 μl
of Nonidet P-40; after 3 min at room temperature, cells were vor-
texed and the cytosolic fraction was obtained by centrifugation for
5 min at 2500 ×g. The nuclear pellet was resuspended in 60 μl of
high-salt extraction buffer (20 mM Hepes, pH 7.9, 0.4 M NaCl, 1 mM
EDTA containing protease and phosphatase inhibitors) and incubated
with shaking at 4 °C for 1 h. The nuclear extract was centrifuged for
5 min at 16,000 ×g and the supernatant stored at −80 °C. Protein
concentration was determined using the Bradford assay.
Nuclear protein extracts (20 μg) or conditioned media (2 μg) were
resolved by SDS-PAGE after heat denaturing in the presence or ab-
sence of 5% β-mercaptoethanol, respectively. Proteins were trans-
ferred to nitrocellulose membranes and analyzed by Western blot as
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obtaining volumograms using Multi Gauge v3.0 (Fujiﬁlm). Data
from nuclear extracts were normalized against the intensity of the
bands corresponding to lamin B1, and data from conditioned media
against MMP-2 bands (both lamin B1 expression and levels of secret-
ed MMP-2 were unaltered upon HDAC-inhibitor treatments under
the experimental conditions used).
2.4. Quantitative real-time PCR
Total RNA was puriﬁed from cell cultures using the RNAqueous kit
(Ambion, Austin, TX) according to manufacturer's instructions. Each
RNA sample was reverse transcribed into cDNAs using the “High Ca-
pacity Reverse Transcription kit” from Applied Biosystems (Alcoben-
das, Spain). MMP-11 mRNA expression was quantiﬁed using SYBR
Green staining and primers 5′-CGATGCTGCTGCTGCTGCTCCAG-3′
(forward, 75–97) and 5′-TGGCGTCACATCGCTCCATACCTTTAG-3′ (re-
verse, 448–422) in a 7900HT Fast Real-Time PCR System from Applied
Biosystems. The real-time PCR thermal conditions were 2 min at
50 °C, 10 min at 95 °C, followed by 40 cycles each at 95 °C for 15 s
and 60 °C for 1 min. The relative real-time PCR quantiﬁcation was
based on the ΔΔCT method using 18S rRNA as reference endogenous
gene (speciﬁc QuantiTect primer set QT00199367 from Qiagen, Hil-
den, Germany).
2.5. Luciferase reporter assay
One microgram of DNA was transfected into exponentially grow-
ing cells in 24-well plates with Escort IV (Sigma). After 20 h, the me-
dium was replaced by a fresh one containing butyrate or TSA. After
24 h treatment, cells were lysed and luciferase activity was measured
in a Lumat LB 9507 luminometer (Berthold, Germany) using the Lu-
ciferase Reporter Gene Assay from Roche (Mannheim, Germany).
For dual luciferase assays, 500 ng of the indicated plasmid was
transfected together with 500 ng pRL-TK (Promega, Alcobendas,
Spain) into exponentially growing cells in 24-well plates with Escort
IV (Sigma). After 20 h, the medium was replaced by a fresh one and
further incubated for 24 h. Fireﬂy and Renilla luciferase activities pre-
sent in cellular lysates were assayed using the Dual-Luciferase Re-
porter Assay System (Promega). Fireﬂy luciferase data were
normalized for the corresponding transfection efﬁciency by using
the Renilla luciferase activity of each sample.
Plasmids containing different fragments of the promoter region of
MMP11 (0.1-ST3, 0.45-ST3, 2.5-ST3 and 2.5-ST3-ΔAP1) [29,30] were
cloned into the pGL3-Basic reporter vector (Promega). pGL3-control
plasmid (also from Promega) was used as a negative control for
butyrate and TSA promoter induction. In addition, we have designed
synthetic mutants (Genscript, Piscataway, NJ) from the three Sp1
sites located in the 0.1-ST3 fragment, either individually (M1: −68/
−63, M2: −41/−36 and M3: −25/−20), or in combination (M12,
M13, M23 and M123) by replacement of the consensus sequence
GGGCGG by TTTCTT, and cloned them into the pGL3-Basic vector.
The effect of the speciﬁc inhibitors for p38-MAPK (SB203580),
JNK-MAPK (SP600125), and ERK1/2-MAPK (PD98059) (all from
Sigma) on MMP11 promoter activity was analyzed after preincuba-
tion for 2 h at the indicated concentrations (described in the litera-
ture [31] and previously tested in our group with BCS-TC2 cells
[24]) and further treatment with butyrate or TSA for 24 h. Incubations
with mithramycin A were carried out for 24 h together with butyrate
and TSA. MAPK-inhibitors were dissolved in DMSO and mithramycin
A in methanol; the corresponding controls contained an equivalent
amount of the vehicles. In order to be able to compare directly pro-
moter activity and protein levels, conditioned media obtained in the
presence of mithramycin A or ERK1/2 inhibitor were collected from
exponentially growing cultures (~50% conﬂuence).2.6. EMSA
Double stranded oligonucleotides covering different regions of the
0.1-ST3MMP11 promoter fragment were end-labeled with [γ-
32
P]ATP
using T4 polynucleotide kinase. Unincorporated ATP was removed by
centrifugation in G-50 spin columns (Amersham Biosciences, Piscat-
away, NJ). Nuclear proteins (5 μg) were incubated with binding buffer
(5% glycerol, 15 mM Tris pH 7.5, 1.5 mM dithiothreitol, 1.5 mM EDTA,
0.5 mM MgCl2), 2 μg poly(dI-dC), 20 μg/ml BSA and the radiolabeled
probe for 30 min at room temperature. DNA–protein complex was re-
solved by electrophoresis in 4% nondenaturing polyacrylamide gel
electrophoresis (PAGE) in 0.5× Tris–borate–EDTA (TBE) buffer. The
gels were dried and analyzed by autoradiography. Supershift was per-
formed by subsequent incubation of the reaction mixture for 15 min
at room temperature with antibodies against Sp1, Sp3, MAZ and
ZBP-89. Competition studies were carried out in the presence of
100-fold molar excess unlabeled probes.2.7. Chromatin immunoprecipitation (ChIP)
ChIP procedures were performed according to [24]. Brieﬂy, isolat-
ed nuclei from formaldehyde-crosslinked cell cultures were lysed and
the crosslinked chromatin was sonicated to yield fragments of around
300 bp. Diluted soluble chromatin fragments were precleared with
blocked Protein G Dynabeads (Invitrogen, Barcelona, Spain) to dis-
card non-speciﬁcally-bound chromatin fragments. Immunofractiona-
tion of complexes was carried out by adding 2 μg of the
corresponding antibodies (anti-Sp1 or anti-Smad2/3) to aliquots con-
taining 50 μg DNA each. The immunocomplexes were recovered by
centrifugation after adding blocked Protein G Dynabeads and exten-
sively washed. An aliquot of the crosslinked chromatin was treated
as before, but in the absence of the antibody (n.a. fraction) and the
ﬁrst supernatant, after the immunoprecipitation, was saved as Input
fraction. Immunoselected chromatin was eluted and the formalde-
hyde crosslinking was reverted. The DNA from all samples was puri-
ﬁed with a PCR puriﬁcation kit (Sigma) and used for PCR analysis
(38 cycles with a 60 °C annealing temperature) using a speciﬁc prim-
er pair [forward: 5′-TGCTAGGAGAGTTCAGAACAAAAGG-3′ (−100/
−76); reverse: 5′-GCGCTGCGGAGCCAG-3′ (+36/+22)]. PCR frag-
ments were size-fractioned by 2% agarose gel electrophoresis, stained
with ethidium bromide and analyzed on a Gel Doc XR photodocu-
mentation system from Bio-Rad.2.8. Protein immunoprecipitation
Immunoprecipitation was carried out by incubation of 50 μl Pro-
tein G Dynabeads with 2.5 μg antibody against Sp1 or with anti-
Smad2/3 for 20 h at 4 °C. After extensive washing of the immuno-
complexes with PBS/BSA (BSA 5 mg/ml), the immunofractionation
was carried out adding 100 μg of nuclear proteins and incubating
for 2.5 h at 4 °C. Immunoprecipitated material was washed 3 times
in PBS/BSA and proteins were eluted from the Dynabeads. Detection
was performed byWestern blot as described earlier using the prima-
ry mouse monoclonal antibodies pan-acetyl-lysine, or anti-human
p53, or goat polyclonal antibodies anti-human Sp1 or anti-human
Smad2/3. Peroxidase-conjugated mouse TrueBlot ULTRA anti-
mouse IgG and peroxidase-conjugated goat TrueBlot anti-goat IgG,
that avoid the detection of the ~55 kDa heavy and ~23 kDa light
chains of the immunoprecipitating antibody, were used as secondary
antibodies. No commercial antibodies to our knowledge have been
yet raised against human acetyl-Smad2/3; thus, identiﬁcation of
acetylated Smad in the immunoprecipitated materials was based
on the electrophoretic mobility of the band as previously described
[32].
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Cells were detached by trypsinization and allowed to recover for
30 min in complete culture medium. After washing twice with PBS,
5×105 cells were resuspended in 500 μl PBS containing 0.1% (w/v)
BSA and 0.02% (w/v) azide. Cells were ﬁxed in cold 3.7% formalde-
hyde and permeabilized with 0.1% Triton X-100 in PBS. The cell sus-
pension was incubated in the presence of 100 μl of the appropriate
dilution of goat polyclonal antibody anti-human MMP-11 (C-20) for
1 h at 37 °C in the dark. Afterwards, cells were again washed twice
with PBS/BSA/azide, and incubated with 100 μl of the appropriate di-
lution of FITC-conjugated rabbit anti-goat IgG monoclonal antibody
for 1 h at 37 °C in the dark. Finally, cells were washed twice with
PBS/BSA/azide, resuspended in 300 μl and analyzed in a FACScan
(Becton-Dickinson, San José, CA), as described [28].
2.10. Other procedures
The differences between the mean values were analyzed with Sig-
maPlot v 11.1 (Systat Software, Erkrath, Germany) and using Stu-
dent's t-test (two-tailed). Statistical signiﬁcance was considered to
be achieved at the pb0.05 level.
Prediction of the transcription factors binding sites in the MMP11
promoter was carried out with MatInspector v7.7.3 using library
v8.2, AliBaba 2.1 program and TFSEARCH 1.3.
3. Results
3.1. Expression of MMP-11 in BCS-TC2 cells
The ﬁrst approach was to verify whether MMP-11 was expressed
in human colon adenocarcinoma epithelial cells using as a positiveFig. 1. Expression of MMP-11 in human colon adenocarcinoma and RD cells. Detection of M
tioned media from RD cells after treatment with PMA and retinoic acid isomers (t-RA and
treatment of BCS-TC2 cells with 4 mM butyrate and 0.5 μM TSA for 48 h. Controls for TSA t
the right panel, conditioned media were preincubated for 12 h at 37 °C with 10 μg α2-m
three independent experiments are shown. (D) Quantitative real-time reverse-transcriptio
24 h. Data are normalized to 18S rRNA levels as internal control, and a value of 1 is assig
four different experiments (**, pb0.01). (E) Cellular MMP-11 expression was analyzed by
cells without (dashed lines) or after treatment with 4 mM butyrate or TSA 0.5 μM for 24 h.expression control the human rhabdomyosarcoma RD cells [5]. West-
ern blot analysis of conditioned media from BCS-TC2, Caco-2, HT29
and RD cells is shown in Fig. 1A. The three studied colon adenocarci-
noma cells express MMP-11 at different levels. The lowest expression
of MMP-11 was observed in HT29 and RD cells in which no active
form was detected in the culture media. The highest expression
among colon adenocarcinoma cells was found in BCS-TC2 cells. The
treatment of RD cells with several classic activators of the MMP-11
expression, such as PMA and all-trans and 9-cis retinoic acid, revealed
a clear increase in the protein levels of the MMP-11 proenzyme
(Fig. 1B), as previously described [7].
The effect of the HDAC inhibitors butyrate and TSA on the expres-
sion of MMP-11 in BCS-TC2 cells has been analyzed. MMP-11 was
detected in all the samples, at least in the proenzyme form
(~55 kDa). Treatment for 48 h with 0.5 μM TSA or 4 mM butyrate in-
creased the level of the active processed form (~44 kDa), whereas the
proenzyme was almost unaffected (Fig. 1C, left panel). Densitometric
analysis of different blots from three independent experiments
revealed that the overall MMP-11 content signiﬁcantly increases
(pb0.05) 1.4-fold after butyrate treatment and 1.7-fold after TSA
treatment, using as loading control the expression of MMP-2 that is
unaffected by HDAC inhibitors. The ratio between the active and pro-
enzyme forms increased 3.8-fold and 6.5-fold after butyrate or TSA
treatments, respectively (pb0.01). Incubation of conditioned media
with α2-macroglobulin speciﬁcally removed the lower molecular
mass band. This conﬁrms the identiﬁcation of the 44 kDa band as
the active MMP-11 form (Fig. 1C, right panel).
Quantitative RT-PCR assays using mRNA extracted from cells
treated 24 h with butyrate or TSA are shown in Fig. 1D. The expres-
sion of MMP-11 mRNA was found to increase about 1.5- to 2.0-fold
in BCS-TC2 cells treated with TSA or butyrate, respectively
(pb0.01).MP-11 by Western blot in (A) conditioned media from different cells, and (B) condi-
9c-RA). (C) Western blot of MMP-11 and MMP-2 in conditioned media obtained after
reatment were incubated with the same concentration of DMSO as in treated cells. In
acroglobulin, that forms complexes with active MMP-11. Representative blots from
n PCR was carried out after treatment of cells with 4 mM butyrate and 0.5 μM TSA for
ned to the corresponding untreated control. Data represent mean values (±S.D.) for
ﬂow cytometry (mean ﬂuorescence intensities between brackets) in permeabilized
Histograms are representative of three different experiments.
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cytometry (Fig. 1E). Data revealed not only the expression of MMP-11
but also that butyrate and TSA treatments increased the mean ﬂuo-
rescence intensity around 1.5- and 2-fold, respectively.3.2. Basal activity of MMP11 promoter
Several fragments from the MMP11 promoter controlling the
expression of ﬁreﬂy luciferase together with a control plasmid
with a strong promoter controlling the expression of Renilla lucif-
erase were transfected into BCS-TC2 cells. Fig. 2A shows a schemat-
ic representation of the promoter fragments with the potential
binding sites for transcription factors as deduced from the MMP11
promoter sequence analysis and those described in the literature
[5,6,29].
The longest promoter fragment used (2.5-ST3) showed the lowest
basal activity values suggesting the presence of distal inhibitory re-
gions (Fig. 2B). In fact, removal of the AP-1 site located at −2419
(2.5-ΔAP1-ST3 fragment) increased around 1.5-fold the promoter ac-
tivity. The presence of other silencing elements in the region between
−2179 and−450 is suggested by the fact that the higher basal activ-
ity was achieved with the 0.45-ST3 fragment. Removal of the DR1-
RARE containing sequence (0.1-ST3 fragment) did not have any sig-
niﬁcant effect.Fig. 2. BasalMMP11 promoter activities and effects of butyrate and TSA treatments. (A) Sche
the binding sites for transcription factors relative to the transcription start position (+1)
repeat-retinoic acid responsive element; TRE, thyroid hormone response element; PEA-3,
MMP11 promoter constructs in BCS-TC2 cells measured with dual luciferase assays in exp
2.5-ST3 construct (**, pb0.01). (C) Effect of butyrate or TSA treatment (24 h) on the lucife
ST3 construct (dotted line) (pb0.01in all comparison between butyrate or TSA treatments an
with the different constructs compared to the 2.5-ST3 construct; ##, pb0.01 idem for TSA t
luciferase activity of the 0.1-ST3 construct. Data are expressed as fold-induction referred to
ments with triplicate samples.3.3. Effect of butyrate and TSA on MMP11 promoter activity
In order to check if the modiﬁcation in MMP-11 expression after
butyrate or TSA treatments was correlated with changes in the pro-
moter activity, the effect of both agents on the transcriptional activity
ofMMP11 promoter fragments was analyzed (Fig. 2C). Butyrate treat-
ment induced 6- to 10-fold increase in the promoter activity of all the
analyzed fragments compared to basal levels (pb0.01). Taking into
account that even the smaller promoter fragment (0.1-ST3) induces
a signiﬁcant increase in luciferase activity, the existence of butyrate
responding elements can be suspected within the proximal promoter
region (−110 to +13). TSA treatment also induced an increase in the
activity of the promoter, but lower than that observed with butyrate,
ranging from around 3-fold for the 0.45-ST3 fragment to around 6-
fold with 2.5-ΔAP1-ST3 (pb0.01).
We have also analyzed the effect of butyrate concentration on the
luciferase activity of the 0.1-ST3 fragment (Fig. 2D). A dose-dependent
increase in activity is observed, reaching saturation at 4 mMconﬁrming
that this concentration is optimal to observe transcriptional effects of
this HDAC inhibitor as we have previously reported [24].
3.4. Binding of transcription factors to the basal MMP11 promoter
Taking into account that the 0.1-ST3 promoter fragment shows a
high basal luciferase activity and a clear response to butyrate, theme of the differentMMP11 promoter fragments employed in luciferase assays showing
(AP-1, activator protein-1; C/EBP, CCAAT/enhancer binding protein; DR-RARE, direct
polyoma enhancer A binding protein-3). (B) Basal promoter activity of the different
onentially growing cells. Data is expressed in arbitrary units with a value of 1 for the
rase activities of MMP11 promoter fragments referred to the basal activity of the 2.5-
d their respective controls; *, pb0.05, **, pb0.01 butyrate treatment in cells transfected
reatments). (D) Concentration-dependent effect of butyrate treatment for 24 h on the
untreated cells, and correspond to mean values (±S.D.) of three independent experi-
575J.I. Barrasa et al. / Biochimica et Biophysica Acta 1823 (2012) 570–581binding of transcription factors to this promoter region was studied.
Using several prediction programs we have detected potential bind-
ing sites for transcription factors previously related with the response
to butyrate in other genes, such as MAZ, ZBP-89 and Sp1/Sp3. Accord-
ingly, we designed several oligonucleotides for EMSA and supershift
assays that covered the complete sequence of the 0.1-ST3 fragment
containing differential transcription binding sites (Fig. 3A).
EMSAs with nuclear extracts obtained after treatment with buty-
rate and TSA were carried out to check if they were able to modify
the position or intensity of some of the bands. Supplementary Fig.
1A shows several bands whose intensity remained mainly unaltered
after the treatments with the four different 0.1-ST3 probes. Competi-
tion assays (Supplementary Fig. 1B) conﬁrmed that the upper band
(marked with an arrow) was speciﬁcally competed out with anFig. 3. Expression of transcription factors in BCS-TC2 cells and supershift assays in the 0.1-ST
of the different probes designed for the EMSAs. A computational prediction of the potential
related; ZBPF, Zinc binding protein factor; ZBP-89, zinc ﬁnger binding protein-89; Sp1/Sp3 bi
Smad2/3 were carried out using nuclear extracts from BCS-TC2 cells treated with 4 mM but
tion. Blots using anti-lamin B1 were used as loading controls. Representative blots from three
described in (A) and speciﬁc antibodies against: (left panel) Sp1and Sp3, and (right panel) M
the speciﬁc shift band (white arrow) and in the appearance of a new supershifted band (bla
of at least three independent experiments.excess cold probe but not affected by an unrelated cold probe. Taking
into account that HDAC inhibitors were unable to modify the EMSA
proﬁles, we ﬁrst checked the expression of these factors in nuclear
extracts and then analyzed by supershift assays their potential bind-
ing to sequences included in the 0.1-ST3 probes.
The expression of Sp1, Sp3, ZBP-89, MAZ and of a binding partner
of Sp1, Smad2/3, was veriﬁed by Western blot analyses of nuclear ex-
tracts from untreated and HDAC inhibitor-treated BCS-TC2 cells
(Fig. 3B). Lamin B1 levels were used as control of protein loading. Ex-
pression of Sp1 was not signiﬁcantly modiﬁed by butyrate or TSA
treatments, even at high butyrate concentrations (Fig. 3C). Regarding
Sp3, three clearly differentiated bands were observed, one of 100 kDa
and two of approximately 60 kDa. Butyrate and TSA treatments in-
creased the level of the 100 kDa isoform that corresponds with the3 region of theMMP11 promoter. (A) Sequences of the 0.1-ST3 promoter fragment and
transcription factors binding sites is shown (MAZR, myc-associated zinc ﬁnger protein
nding sites are reverse shaded). (B) Western blot analysis of Sp1, Sp3, ZBP-89, MAZ and
yrate or 0.5 μM TSA for 24 h. (C) Sp1 expression in dependence of butyrate concentra-
independent experiments are shown in B and C. (D) Supershift assays using the probes
AZ and ZBP-89. Interaction with the Sp1 antibody resulted in a signiﬁcant decrease in
ck arrow). The other antibodies did not induce band supershift. Gels are representative
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ternal translation) remained unaffected. ZBP-89 expression was
mainly unaffected whereas MAZ decreased with butyrate treatment
and slightly increased with TSA. In addition, Smad2/3 expression
was analyzed in nuclear extracts; Smad2 (lower mobility band)
showed a higher expression than Smad3 (higher mobility band).
Whereas almost no variations were detected in Smad2 expression
with butyrate and TSA, an upregulation of Smad3 was observed main-
ly with butyrate treatment (Fig. 3B). Regarding supershift assays, Sp1
antibodies, but not those against Sp3, the other closely related mem-
ber this family of transcription factors, were able to decrease the mo-
bility of the speciﬁc EMSA band (black arrow in Fig. 3D, left panel). On
the other hand, MAZ and ZBP-89 antibodies were not able to alter the
mobility of any band (Fig. 3D, right panel).
3.5. Binding of Sp1/Smad complexes to the MMP11 promoter
In order to identify the presence of other transcription factors
bound to Sp1 we carried out immunoprecipitation assays using
anti-Sp1 antibodies. Immunoprecipitated material was analyzed by
Western blot using anti-Sp1 antibodies (Fig. 4A, left panels); as
expected, blots yielded a strong band around 100 kDa corresponding
to Sp1. In a ﬁrst approach, and taking into account that butyrate and
TSA are HDAC inhibitors, we used pan-acetyl-Lys antibody to develop
blots and only a major band around 50 kDa was detected. We tried to
identify this acetylated protein among previously described Sp1 part-
ners. On a ﬁrst step, we checked up the presence of acetylated-p53
that has been described associated with Sp1 in multiprotein com-
plexes that regulate the transcriptional activity of speciﬁc genes
[33], but blots were negative (data not shown). On the other hand,
Western blot analysis revealed that Smad2 (band of ~50 kDa) co-
immunoprecipitated with Sp1 in nuclear extracts of BCS-TC2 cells.
Immunoprecipitation with anti-Smad2/3 antibodies conﬁrmed the
complex between Sp1 and Smad2 (Fig. 4A, right panels).
Butyrate and TSA treatments increased the levels of Sp1/Smad2
complexes and, additionally, there was a clear induction in the acety-
lation state [32] of Sp1-bound Smad2 after butyrate and TSA treat-
ment. To further conﬁrm the binding of Sp1/Smad2 complex to theFig. 4. Interactions between Sp1 and Smad in theMMP11 promoter. (A) Immunopreci-
pitated material with antibodies against Sp1 or Smad2/3 from nuclear extracts of BCS-
TC2 cells treated with 4 mM butyrate or 0.5 μM TSA for 24 h were probed for the pres-
ence of Sp1, Smad2/3 and pan-acetyl-Lys by Western blot analysis with the corre-
sponding antibodies. (B) ChIP assays were performed to conﬁrm the binding of Sp1
and Smad transcription factors to the MMP11 promoter in cells without butyrate (−)
or after a 24 h treatment with butyrate (+), and in the absence (−Mit A) or presence
(+Mit A) of mithramycin A. The immunoprecipitated samples using antibodies against
Sp1 and Smad were analyzed by PCR using the primers described in Materials and
methods. As controls for the ChIP experiment, PCR was also carried out with the super-
natant of a mock immunoprecipitation without antibodies (Input; diluted 1:100) and
with samples obtained under these no-antibody (n.a.) conditions.MMP11 promoter, we performed ChIP assays using speciﬁc antibodies
for Sp1 and Smad2/3. Chromatin immunoprecipitation conﬁrmed not
only Sp1 binding (previously observed by supershift assays, Fig. 3D,
left panel) but also showed Smad binding to the MMP11 promoter.
Butyrate treatment slightly decreased Sp1 binding (~1.4-fold lower)
but signiﬁcantly enhanced the interaction of Smad with the promoter
(~2-fold; Fig. 4B, −Mit A). The binding of Sp1 is speciﬁc, as mithra-
mycin A (an antibiotic that is able to bind to GC-rich sequences in sev-
eral promoters thus interfering with the binding of Sp1 to these sites
[34]) impeded the binding of this transcription factor either in the ab-
sence or presence of butyrate (Fig. 4B, lower panel, +Mit A). Howev-
er, in the presence of mithramycin A, Smad is still bound to the
promoter region although binding of Sp1 is abolished. After butyrate
treatment, Smad is no longer attached to this region of the MMP11
promoter (Fig. 4B, +Mit A).3.6. Inhibition of Sp1 binding to the MMP11 promoter
To conﬁrm the role of Sp1 in the activation of theMMP11 promot-
er, both in basal conditions and after butyrate or TSA treatment, lucif-
erase assays in the presence of mithramycin A were performed.
Mithramycin A treatment signiﬁcantly reduces MMP11 promoter ac-
tivity in BCS-TC2 cells. Under basal conditions, transcriptional activity
of the 2.5-ST3 (Fig. 5A) and 0.1-ST3 (Fig. 5B) fragments was reduced
around 40% and 15%, respectively. Promoter activation induced by
butyrate was signiﬁcantly reduced by mithramycin A (around 40–
50% decrease in both promoter fragments), being this reduction
lower with TSA (around 25%).
Additionally, the effect of mithramycin A on the MMP-11 levels in
conditioned media from exponentially growing cells was analyzed by
Western blot (Fig. 5C). Under these conditions, butyrate induced a higher
increase in the overall MMP-11 levels (3.5-fold) than that observed in
subconﬂuent cultures (1.4-fold; Fig. 1C)without signiﬁcantmodiﬁcations
in the behavior with TSA. Mithramycin A reduced the increase in MMP-
11 expression induced by butyrate (from 3.5 down to 2-fold increase),
this effect beingmore evident in the pro-MMP-11 form than in the active
one. Mithramycin A effects were less marked in the TSA treatment.
To further conﬁrm the essential role of Sp1 in the basal expression
ofMMP11 as well as in the induction by HDAC inhibitors, mutations of
the individual Sp1 sites in the 0.1-ST3 fragment and combinations of
these mutations were cloned into pGL3-Basic vector. Luciferase as-
says in the absence (Fig. 6A) and in the presence of butyrate
(Fig. 6B) or TSA (Fig. 6C) were carried out with the wild-type frag-
ment and the seven different mutant constructs. Basal expression
was reduced around 50% when either M1 or M2 were analyzed, and
was almost completely abolished when the M12 or the M123 con-
structs were considered. On the other hand, mutation of the
−25/−20 Sp1 did not signiﬁcantly alter luciferase activity compared
to the wild-type fragment. Regarding the effect of butyrate and TSA,
the −68/−63 Sp1 site seems to be the main HDAC-inhibitor re-
sponse element as its mutation reduces by 80% or 65% the transcrip-
tional induction after butyrate or TSA treatments, respectively,
when luciferase activities are referred to that of the wild-type basal
activity. Mutation of the −41/−36 Sp1 site reduces by around 50%
the transcriptional activation induced by both treatments, being
equivalent to the decrease observed in basal activity with this muta-
tion. Again, a cooperative effect was observed by combination of the
−68/−63 mutation with the other two sites. No signiﬁcant effect
was observed by mutation of the−25/−20 site alone. Supplementa-
ry Fig. 2 represents these same data but the luciferase activity fold-
induction after HDAC inhibitor treatments is referred to the basal ac-
tivity of the corresponding mutant instead of that of the wild-type. In
this way, it can be better observed that only the mutation of the
−68/−63 Sp1 site (or its combination with the other two mutations)
affects the transcriptional activation after butyrate or TSA treatments.
Fig. 5. Role of Sp1 in butyrate and TSA activation of the MMP11 promoter and protein
expression. Luciferase activity was measured in BCS-TC2 cell homogenates obtained
after transfection with (A) the 2.5-ST3 or (B) the 0.1-ST3 promoter fragments, and fur-
ther treatment for 24 h with butyrate or TSA in the presence or absence of 200 nM
mithramycin A. All the samples contained the same concentration of DMSO. Data cor-
respond to mean values (±S.D.) from three independent experiments with triplicate
samples (*, pb0.05; **, pb0.01). (C) Western blot detection of MMP-11 in conditioned
media from BCS-TC2 cells after treatment with butyrate or TSA in the absence or pres-
ence of mithramycin A (all the samples contain the same concentration of DMSO and
methanol). A representative blot of three independent experiments is shown.
Fig. 6. Luciferase activity of pGL3-Basic constructs containing the wild-type 0.1-ST3
promoter fragment or mutations of the Sp1 consensus sequences. Luciferase activity
was measured in BCS-TC2 cell homogenates obtained after transfection with the 0.1-
ST3 wild-type (WT) or mutant constructs. A scheme of the position of the different mu-
tations is shown in the upper part of the ﬁgure. After transfection, cells were further in-
cubated for 24 h in the absence (A, basal activity) or presence of 4 mM butyrate (B) or
0.5 μM TSA (C). Activity is expressed as fold induction referred to the activity of
untreated cells transfected with the wild-type construct. Data correspond to mean
values (±S.D.) from three independent experiments with triplicate samples. Muta-
tions were obtained by replacement of the Sp1 consensus sequences GGGCGG by
TTTCTT; M1: −68/−63; M2: −41/−36; M3: −25/−20; M12: mutations M1 and
M2; M13: mutations M1 and M3; M23: mutations M2 and M3; M123: mutations M1,
M2 and M3. (**, pb0.01 for comparisons between mutant constructs vs. wild-type; #,
pb0.05 and ##, pb0.01 for comparisons between mutant constructs with the same
number of mutations).
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To gain further insight into the mechanisms involved in the induc-
tion of the transcriptional activity of MMP11 promoter (2.5-ST3 con-
struct) by butyrate and TSA, luciferase assays were performed in the
presence of speciﬁc inhibitors of the main members of the MAPK fam-
ily. Inhibitors of p38-MAPK and JNK (SB203580 and SP600125, re-
spectively) did not modify the activation of the MMP11 promoter by
butyrate or TSA (Fig. 7). However, the effect of butyrate and TSA
was signiﬁcantly reduced in the presence of the speciﬁc ERK1/2 in-
hibitor PD98059 (Fig. 7). This effect is dose-dependent and abolishes
butyrate- and TSA-induced activation at 50 μM (Fig. 8A). Luciferase
assays were also carried out with the 0.1-ST3 construct in the pres-
ence of PD98059 (Fig. 8B). The effect of butyrate and TSA was also sig-
niﬁcantly reduced in a dose-dependent manner, although the
transcriptional activation by these HDACs inhibitors was not
completely suppressed even at the highest concentration of
PD98059 used. Basal transcriptional activity was not signiﬁcantly af-
fected by the ERK1/2 inhibitor in cells transfected either with the
2.5-ST3 or the 0.1-ST3 promoter fragments.Finally, the effect of PD98059 on the MMP-11 protein levels was
analyzed by Western blot of conditioned media from exponentially
growing cells (Fig. 8C). Inhibition of ERK1/2 pathway signiﬁcantly re-
duced the increase in protein levels induced by butyrate treatment
(from 3.5-fold down to 1.9-fold), being this effect higher for the pro-
enzyme levels. Inhibition of ERK1/2 in TSA-treated cells induced a de-
crease in the proenzyme levels without affecting the overall
expression of MMP-11. All these results suggest that ERK1/2 signaling
Fig. 7. Involvement of MAP-kinases in butyrate and TSA activation of the MMP11 pro-
moter. Luciferase activity was measured in BCS-TC2 cell homogenates obtained after
transfection with the 2.5-ST3 construct and treatment for 24 h with butyrate or TSA
in the presence or absence of 25 μM SB203580 (p38-MAPK inhibitor), 10 μM
SP600125 (JNK inhibitor), or 10 μM PD98059 (ERK1/2 inhibitor). Activity is expressed
as fold induction referred to the activity of butyrate-untreated transfected cells. Data
correspond to mean values (±S.D.) from four independent experiments with triplicate
samples (*, pb0.05 and **, pb0.01 comparisons vs. controls without butyrate or TSA; #,
pb0.05 and ##, pb0.01 comparisons vs. corresponding group without MAPK
inhibitors).
Fig. 8. Involvement of ERK1/2-MAPK in butyrate and TSA activation of the MMP11 pro-
moter and protein expression. Luciferase activity was measured in BCS-TC2 cell homoge-
nates obtained after transfection with (A) the 2.5-ST3 or (B) the 0.1-ST3 constructs, and
further treatment for 24 hwith butyrate or TSA in thepresence or absence of different con-
centrations of the PD98059 ERK1/2 inhibitor. Activity is expressed as fold induction re-
ferred to the activity of butyrate-untreated transfected cells. Data correspond to mean
values (±S.D.) from three independent experiments with triplicate samples (*, pb0.05;
**, pb0.01). (C) Western blot detection of MMP-11 in conditioned media from BCS-TC2
cells after treatment with butyrate or TSA in the absence or presence of 10 μM ERK1/2 in-
hibitor. A representative blot of three independent experiments is shown. All the samples
contained the same concentration of DMSO.
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promoter.
4. Discussion
MMP-11 expression has been normally associated with stromal ﬁ-
broblasts surrounding aggressive tumors although it has also been
detected in murine macrophages and Hca-F mouse hepatocarcinoma
cells [8–13,15,35]. The expression of MMP-11 in non-stromal cells
was ﬁrstly observed by immunohistochemistry in a group of aggres-
sive primary mammary carcinomas (metaplastic carcinomas),
whose cells had undergone a degree of epithelial-to-mesenchymal
transition with mesenchymal attributes as spindle/fusiform shape
and vimentin expression [15]. Regarding the expression of MMP-11
in colonic tumors, this protein has only been found in the stroma sur-
rounding the tumor [11,35], but now we have detected its expression
in three different human colon adenocarcinoma cell lines (BCS-TC2,
HT-29 and Caco-2) from epithelial origin. To validate our detection
system, we have veriﬁed the well-studied expression of MMP-11 in
conditioned media from the rhabdomyosarcoma cell line RD in con-
trol conditions and after induction with phorbol esters or retinoic
acid [7,30].
Although there is an extensive knowledge on the regulatory cis-
elements and corresponding trans-activators involved in the tran-
scriptional regulation of several members of the MMP family, scarce
information can be found regarding human MMP11 [6,29]. The
MMP11 promoter contains several regulatory elements not common
to other members of this family, or that strongly differ in their pro-
moter activity regulation [29]. Thus, while the expression of others
MMP genes is repressed by retinoic acid, it activates MMP11 expres-
sion through a DR1-RARE sequence located in its proximal promoter
[7].MMP11 gene is also characterized by the absence of an AP-1 bind-
ing site in its proximal promoter, common to other members of the
MMP family, although other AP-1 sites are located in distal regions
of its promoter.
To gain insight into theMMP11 transcriptional regulation we have
analyzed different constructs from its promoter. Several inhibitory el-
ements are located in distal regions, as the lower activity levels are
achieved with the longest promoter fragment used. One of these in-
hibitory elements corresponds to an AP-1 site, since its deletion(2.5ΔAP1-ST3 construct) is correlated with an increased transcrip-
tional activity. The data obtained show that the main regulatory re-
gion within this promoter is located between −110/+15 bp of the
gene relative to the transcription start site.
We have ﬁrst described the transcriptional regulation ofMMP11 and
the protein expression through Sp1 in BCS-TC2 cells. The presence of
several GC-boxes (potential Sp1 binding sites) in the proximal regions
of the MMP11 promoter has been reported [29]. In addition, two indi-
rect observations point out a potential role of Sp1 inMMP11 transcrip-
tion: i) the coexpression of Sp1 and MMP-11 proteins in gastric
tumors [14], and ii) a decrease in the TGF-β-induced upregulation of
MMP11 after mithramycin A treatment in pancreatic cells observed in
gene expression proﬁling experiments [36]. However, there are neither
data about the biological meaning of these correlations nor a direct
demonstration of the binding of Sp1 to the GC-rich sequences. Here
we have shown that Sp1 binds to the MMP11 promoter through the
proximal GC-boxes. Mithramycin A interferes with Sp1 binding [34]
and conﬁrms that Sp1 regulates the basal transcriptional activity of
theMMP11. Interestingly, Sp1 has also been described as an important
factor regulating the transcriptional activity of other MMP genes, such
as MMP2 and MMP14, in which Sp1 also binds to proximal GC-boxes,
andMMP9where Sp1 binds to distal ones [37–39].
579J.I. Barrasa et al. / Biochimica et Biophysica Acta 1823 (2012) 570–581Although little is known regarding the epigenetic control of the ex-
pression ofMMP genes, several reports support a general role of tran-
scription factors in this control by recruiting chromatin-remodeling
factors to promoters (for review see [6]). Besides the regulation of
the acetylation status of histones by histone acetyltransferases
(HATs) and HDACs, there is increasing evidence of non-histone pro-
teins involved in transcription that are acetylated at lysine residues
modifying their activity or their binding afﬁnity to promoters [40].
Thus, the acetylation status of both histones and transcription factors
may play an important role in the transcriptional regulation of MMP
genes [26]. Treatment of cells with HDAC inhibitors results in the
down- or up-regulation of gene expression of only a small percentage
of genes aswe have previously reported in BCS-TC2 cells after butyrate
treatment [22].
On this idea, we have studied the effect of butyrate and TSA on the
transcriptional activity of the MMP11 promoter and the involvement
of Sp1/Smad complexes in its regulation in BCS-TC2 cells. We have
conﬁrmed the activation by butyrate and TSA of theMMP11 promoter
with all the fragments employed, even with the shortest one (0.1-
ST3), being this effect stronger with butyrate. RT-PCR analysis clearly
demonstrates a signiﬁcant increase in MMP-11 mRNA levels after the
treatments, which is correlated with an increase in secreted protein
levels mainly from the active/mature form. This is in good agreement
with the described intracellular processing by furin-like serine prote-
ases, which may also act as molecular chaperones facilitating the se-
cretion of the mature form [41]. In any case, the zymogen is also
detected in conditioned media as intracellular activation is not com-
plete and the inactive form can also be secreted [42]. Pro-MMP-11
can be activated extracellularly by other proteases, as urokinase, plas-
min, other MMPs as MMP-3 or even autocatalytically processed [43].
As butyrate has been described to increase the levels of some of these
proteases [44,45], this could explain why the highest increase in the
expression of MMP-11 is observed in the active form. Very little is
known regarding the effect of butyrate on the expression of other
MMPs in colon carcinoma cells. In fact, contradictory ﬁndings have
been reported using different cell lines; butyrate induces MMP-9 ex-
pression without affecting MMP-2 in SW1116 cells [46], while it abol-
ishes the expression of MMP-2 and−9 in other colon carcinoma cell
lines [47].
Taking into account that butyrate is normally associated with ben-
eﬁcial effects in colon carcinogenesis, the induction of MMP-11 ex-
pression by this agent could seem paradoxical as its overexpression
has been usually correlated with bad prognosis. A possible hypothesis
is that BCS-TC2 cells may trigger a pro-survival response against the
pro-apopototic effects of butyrate by increasing the expression of
MMP-11 among other factors. On this idea, it has been described
that the hemopexin domain of some MMPs may induce survival sig-
nals via interaction with membrane receptors [48]. On the other
hand, MMP-11 has been shown to be involved in pro-apoptotic pro-
cesses during development and tissue remodeling processes, which
would be in agreement with the beneﬁcial effect of butyrate in colo-
rectal carcinogenesis. In addition, recent work on several MMPs has
shown that expression of some MMP family members actually pro-
vides a protective and anti-tumorigenic role [49,50], which could be
in good agreement with the induction of MMP-11 by butyrate in
BCS-TC2 cells. In any case, further research is required to better un-
derstand the physiopathological role of this MMP in colon carcinoma
cells.
The in silico prediction of potential binding sites for transcription
factors showed the presence of binding sequences for MAZ, ZBP-89
and Sp1/Sp3, that have been reported to be involved in the response
to butyrate in other genes. However, supershift assays revealed that
only Sp1 was able to bind to the region of the MMP11 promoter that
corresponds with the 0.1-ST3 fragment. This binding was further con-
ﬁrmed in the cells by ChIP. Moreover, we have conﬁrmed that two of
the three Sp1 sites located within the 0.1-ST3 promoter fragment(−68/−63 and−41/−36) seem to be essential for basal expression
of this gene as deduced from the luciferase activity of mutant con-
structs in which individual Sp1 sites, or both simultaneously, were
replaced by a non-consensus Sp1-binding sequence.
Butyrate or TSA treatments did not alter nuclear Sp1 protein
levels, as revealed by Western blot, and its binding afﬁnity to the
MMP11 promoter was not signiﬁcantly modiﬁed according to EMSA,
and only showed a slight decrease after butyrate treatment in ChIP
(in agreement with a previous report indicating that acetylation of
Sp1 may partially reduce Sp1 binding [51]). Previous works have de-
scribed the Sp1-dependent transcriptional activation of several genes
after treatment with HDAC inhibitors without signiﬁcant changes in
the Sp1 protein levels or in its binding afﬁnity to DNA [52,53]. Thus,
the effect of these HDAC inhibitors may result from the post-
translational modiﬁcation of Sp1 or some of its transcription factor
partners. In any case, here we have conﬁrmed the relevance of Sp1
binding for the transcriptional-enhancement of theMMP11 promoter
by HDAC inhibitors by luciferase assays with mutant constructs lack-
ing the Sp1 consensus sequences. Although basal expression was
strongly dependent on both −68/−63 and −41/−36 sites, activa-
tion by butyrate or TSA seems to rely more in the former, as its muta-
tion induces a highly signiﬁcant decrease in MMP11 transcriptional
activation by butyrate and TSA, that is almost completely abolished
when this mutation is combined with that of the other Sp1 sites.
Taking these premises into account, we evaluated the acetylation
status of nuclear Sp1 immunoprecipitates after the different treat-
ments. No acetylation of Sp1 was observed and only a band around
50 kDa was found acetylated that did not correspond to p53. Other
transcription factors, as some members of the Smad family of pro-
teins, have been described as partners of Sp1 [54]. We have veriﬁed
the presence of Smad2 in the Sp1 immunoprecipitates as well as a
slight increase in Sp1/Smad2 complex after butyrate treatment. The
formation of this complex was further conﬁrmed by immunoprecipi-
tation with anti-Smad2/3 antibody. Smad2 levels were quite similar
between controls and treated cells, as occurs in the nuclear extracts,
but there was a signiﬁcant increase in the amount of Sp1 bound to
Smad2 after treatment with the HDAC inhibitors. This increase direct-
ly correlated with a rise in the intensity of the band positive for pan-
acetyl-Lys antibody with identical mobility to Smad2. It is also worth
mentioning that no Smad3 was detected in the immunoprecipitate
even though after butyrate treatment there was an upregulation of
this protein.
Binding of Smad to the proximal promoter region was veriﬁed by
ChIP. After butyrate treatment Smad increased its binding afﬁnity to
this region of the promoter. Taking into account that no consensus
Smad binding elements are present in the analyzed promoter region,
Smad could bind through Sp1. However, when ChIP analysis was car-
ried out in the presence of mithramycin A, Smad was still detected
bound to this promoter region whereas Sp1 binding was completely
abrogated. Thus, either Smad binds directly with low afﬁnity to
non-consensus sequences within this region of the promoter, or it
could be recruited through an alternative partner or to the basal tran-
scriptional complex. Interestingly, when butyrate treatment was car-
ried out in the presence of mithramycin A, neither Sp1 nor Smadwere
found bound to the proximal promoter. As butyrate treatment in-
creases the Smad acetylation status, this may contribute to the disap-
pearance of the unspeciﬁc direct or indirect interaction with the
proximal promoter as it increases the afﬁnity for Sp1 (unbound to
the promoter due to mithramycin).
Smad acetylation has been reported to increase its transactivation
activity and binding to DNA. Smad2 can be acetylated by p300, CBP,
and P/CAF [55], but its acetylation status depends on the equilibrium
between acetylation and deacetylation by HDACs. Thus, butyrate or
TSA treatments increase the acetylation status of Smad2 fostering its
association with Sp1; this may explain the lack of binding of Smad
to the MMP11 proximal promoter in the presence of mithramycin A
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complex with Sp1 which is blocked from binding to the promoter.
The increased acetylation of Smad2 and its association with Sp1
may explain, at least partially, the increased transcriptional activity
of MMP11 promoter detected after both HDAC inhibitor treatments.
Alternatively, butyrate and TSA may inhibit HDACs bound to Sp1 or
Smad. This fact could lead to chromatin relaxation by induction of
an increased acetylation status of histones in the MMP11 gene pro-
moter, facilitating in this way its transcription. A similar mechanism
has been reported for the induction of the TGF-β receptor I gene
after SAHA treatment (other HDAC inhibitor) [56].
Apart from the direct regulation of the activity of transcription fac-
tors through acetylation, HDAC inhibitors can regulate different
MAPK signaling pathways [24,57]. We have previously reported that
butyrate is able to enhance the expression of annexin A1 in BCS-TC2
human colon adenocarcinoma cells by modulation p38-MAPK activity
[24]. In addition, it has been reported that MMPs can be upregulated
by different agents that activate MAPK pathways, especially through
the activation of ERK pathway [58]. Moreover, it has been reported
that ERK phosphorylation is enhanced in colon cancer cells after buty-
rate treatment, and that Sp1 and Smads can be phosphorylated by ac-
tivated ERK [57]. Thus, we checked whether upregulation of MMP11
gene by butyrate or TSA was dependent on MAPK pathways.
We have shown that ERK pathway is essential for the upregulation
of MMP11 by both HDAC inhibitors. PD98059, a speciﬁc ERK activa-
tion inhibitor, induces a dose-dependent decrease in the activation
of the transcriptional activity of the long (2.5-ST3) and short (0.1-
ST3) promoter fragments without affecting basal transcriptional ac-
tivity. The effect of the inhibitor of the ERK1/2 pathway can also be
observed at the protein level. Unfortunately, we have not been able
to detect Sp1 and Smad phosphorylated states using different com-
mercially available antibodies and, thus, we cannot establish whether
ERK activity is directed against these targets or against other compo-
nents of the transcriptional machinery. The nuclear import of Smad2
requires its phosphorylation, but we have not observed variations in
the nuclear level of Smad2 after treatments. Thus, Smad2 phosphory-
lation does not seem to be important for the induction ofMMP11 after
HDAC inhibitors treatment.
5. Conclusions
In summary, we have detected for the ﬁrst time the expression of
MMP-11 in epithelial human colon adenocarcinoma cells. In BCS-TC2
cells, Sp1 binding to the GC-rich region in the proximal promoter of
MMP11 is necessary for transcriptional activity through a protein het-
erocomplex that involves Smad2. Our results show a dual mechanism
of transcriptional control of MMP11 gene upon treatment with HDAC
inhibitors. First, butyrate and TSA directly increase the acetylation
status of Smad2 favoring the association Sp1/Smad2 with a subse-
quent increase in the transcriptional activity and MMP-11 protein
level. Second, whereas the activation of the ERK signaling pathway
is not required for MMP-11 basal expression, it is quite important
for the upregulation of the expression of this gene by HDAC
inhibitors.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbamcr.2011.12.010
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